Dr. Kupfer reports receiving consulting fees from the American Psychiatric Association for serving as the chair of the DSM-5 Task Force.
"I do have to report my Caesar’s disclosure. I’ve had no contact with industry, the pharmaceutical industry, now for seven years. They wouldn’t even recognize me. The only disclosure I have is as a consultant to the APA for the past seven years…"
I’ve highlighted two things – Kupfer’s disclosures and the date the page was released. From the content of his talk I’m guessing the video must’ve been recorded last summer, not long after the DSM-5 was released in May 2013.
ONLINE FIRSTby Robert D. Gibbons, PhD; David J. Weiss, PhD; Paul A. Pilkonis, PhD; Ellen Frank, PhD; and David J. Kupfer, MDJAMA Psychiatry. Published online November 20, 2013.
To the Editor We apologize to the editors and readers of JAMA Psychiatry for our failure to fully disclose our financial interests in an article that reported a diagnostic tool, the Computerized Adaptive Test for Depression [CAT-DI]. Following acceptance of the paper, we disclosed that “The CAT-DI will ultimately be made available for routine administration, and its development as a commercial product is under consideration.” The company that owns the rights to CAT-DI and several related tests is Psychiatric Assessments, Inc [PAI], which uses the trade name of Adaptive Testing Technologies [ATT] on a website describing these tests.Lead author Robert D. Gibbons, PhD, is the president and founder of PAI, which was incorporated in Delaware in late 2011, then registered to do business in Illinois in January 2012. Dr Gibbons awarded “founder’s shares in PAI” to us, yet all 5 of us failed to report our financial interests in connection with our article and again in a Reply to Letters to the Editor regarding the article. Neither PAI nor ATT has released the CAT-DI test [or any other test] for commercial or professional use, but our ownership interests were relevant to the research article and Reply we submitted and should have been disclosed to the editors. Our submitted disclosure lacked transparency, and we regret our omission.
And here’s the operative segment of the timeline leading up to the article referred to in that apology:
|9||11/29/2011||Psychiatric Assessments Inc. incorporated in Delaware [enter File #5072041].|
|10||01/23/2012||Psychiatric Assessments Inc. incorporated in Illinois [enter File #68256313].|
|11||08/31/2012||Yehuda Cohen, a professional management executive, registers Adaptive Testing Technologies website. Mr. Cohen is featured as a principal on the corporate website. .|
|13||11/01/2012||Development of a computerized adaptive test for depression.
by Gibbons, Weiss, Pilkonis, Frank, Moore, Kim, and Kupfer.
Archives of General Psychiatry. 2012 69:1104-12.
"Traditional measurement fixes the number of items administered and allows measurement uncertainty to vary. In contrast, a CAT fixes measurement uncertainty and allows the number of items to vary. The result is a significant reduction in the number of items needed to measure depression and increased precision of measurement."
Dr. Kupfer should have disclosed to APA his interest in PAI in 2012…
It seems like Dr. Kupfer et al are pursuing a strategy of only acknowledging this particular Conflict of Interest when forced, as in the situation with JAMA Psychiatry, and avoiding talking about it otherwise – mirrored so far by the APA President and Board of Trustees. I guess we could call it a hope-it-blows-over plan. So it falls on people like the watchdog who sent me the link to this example to spend time keeping tabs on Dr. Kupfer’s Disclosures. The Task Force tried that hope-it-blows-over strategy with the critiques of Drs. Spitzer and Frances during the DSM-5 Revision period itself, and it didn’t work out as well as they might’ve hoped. Maybe it will work this time.